For PhRMA, There Is Good News And Bad News In The Mid-Term Elections
Executive Summary
The anti-government intervention sentiment coming to Congress in January with the newly elected Republicans presents a tactical challenge to lobbying efforts by the Pharmaceutical Research and Manufacturers of America.
You may also be interested in...
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
"The Pink Sheet" – Most Notable Stories Of 2010
While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.
Pharmaceuticals Not Likely To Be A Target Of Republicans In Coming Congress, Hill Watchers Say
Some issues - such as drug importation or rebates for Medicare/Medicaid dual eligibles - could surface. GOP could make "surgical strikes" on health reform law, including the Independent Payment Advisory Board, if overall repeal of reform law fails.